文献速递糖尿病肥胖与代谢综合征

血液代谢组学指标与2型糖尿病当前及未来血糖控制相关

Blood Metabolomic Measures Associate With Present and Future Glycemic Control in Type 2 Diabetes.
PubMed 文献 · J Clin Endocrinol Metab · 2018-01-01

在四个队列(n=2641)及一个复制队列(n=395)的2型糖尿病患者中分析162项核磁共振代谢组学指标,26项与血糖控制不佳(HbA1c >53 mmol/mol)相关,最强为谷氨酰胺(OR 0.66)。31项与降糖药使用相关。26项中5项(载脂蛋白A1及中高密度脂蛋白亚类)在发现与复制队列中均与随访期间胰岛素起始相关,最强为中高密度脂蛋白胆固醇酯(OR 0.54)。

要点

  • 26项代谢组学指标与血糖控制不佳相关,最强为谷氨酰胺(OR 0.66)。
  • 31项代谢组学指标与降糖药使用相关。
  • 5项指标与随访7年胰岛素起始相关,最强为中高密度脂蛋白胆固醇酯(OR 0.54)。

核心结论

  • 血液代谢组学指标与2型糖尿病当前及未来血糖控制相关,可能为识别治疗失败风险升高者提供线索。

研究设计与样本

  • 在四个队列(n=2641)及一个复制队列(n=395)的2型糖尿病患者中,用核磁共振法分析162项代谢组学指标。
  • 采用线性与逻辑回归校正潜在混杂因素后行荟萃分析,分析指标与HbA1c、六类降糖药及7年随访期间胰岛素起始(n=698)的关联。

主要发现

  • Bonferroni校正后,26项指标与血糖控制不佳(HbA1c >53 mmol/mol)相关,最强为谷氨酰胺(OR 0.66;95% CI 0.61–0.73;P=7.6×10-19)。
  • 与未治疗患者相比,31项代谢组学指标与降糖药使用相关(所有P≤3.1×10-4)。
  • 药物分层分析中,与血糖控制不佳的关联仅受不同降糖药轻度影响。
  • 26项指标中5项(载脂蛋白A1及中高密度脂蛋白亚类)在发现与复制队列中均与随访期间胰岛素起始相关,最强为中高密度脂蛋白胆固醇酯(OR 0.54;95% CI 0.42–0.71;P=4.5×10-6)。

局限性

  • 原文未述局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: We studied whether blood metabolomic measures in people with type 2 diabetes (T2D) are associated with insufficient glycemic control and whether this association is influenced differentially by various diabetes drugs. We then tested whether the same metabolomic profiles were associated with the initiation of insulin therapy. METHODS: A total of 162 metabolomic measures were analyzed using a nuclear magnetic resonance-based method in people with T2D from four cohort studies (n = 2641) and one replication cohort (n = 395). Linear and logistic regression analyses with adjustment for potential confounders, followed by meta-analyses, were performed to analyze associations with hemoglobin A1c levels, six glucose-lowering drug categories, and insulin initiation during a 7-year follow-up period (n = 698). RESULTS: After Bonferroni correction, 26 measures were associated with insufficient glycemic control (HbA1c >53 mmol/mol). The strongest association was with glutamine (OR, 0.66; 95% CI, 0.61 to 0.73; P = 7.6 × 10-19). In addition, compared with treatment-naive patients, 31 metabolomic measures were associated with glucose-lowering drug use (representing various metabolite categories; P ≤ 3.1 × 10-4 for all). In drug-stratified analyses, associations with insufficient glycemic control were only mildly affected by different glucose-lowering drugs. Five of the 26 metabolomic measures (apolipoprotein A1 and medium high-density lipoprotein subclasses) were also associated with insulin initiation during follow-up in both discovery and replication. The strongest association was observed for medium high-density lipoprotein cholesteryl ester (OR, 0.54; 95% CI, 0.42 to 0.71; P = 4.5 × 10-6). CONCLUSION: Blood metabolomic measures were associated with present and future glycemic control and might thus provide relevant cues to identify those at increased risk of treatment failure.

来源:J Clin Endocrinol Metab,查看原文。版权归原作者所有。

引用

  1. 't Hart LM, Vogelzangs N, Mook-Kanamori DO, et al. Blood Metabolomic Measures Associate With Present and Future Glycemic Control in Type 2 Diabetes. J Clin Endocrinol Metab. 2018. PMID: 30113659. doi:10.1210/jc.2018-01165

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。